Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-Analysis

참고문헌 (52)

1. "Cancer stat facts: Female breast cancer" (2019)[URL]
2. Yoon-Sim Yap, "Insights Into Breast Cancer in the East vs the West", JAMA Oncology, 5(10), pp.1489~ (2019), American Medical Association (AMA)[DOI]
3. Howlader N, "US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status", J Natl Cancer Inst (2014)[DOI]
4. Goldhirsch A, "Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
5. Dowsett M, "Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen", J Clin Oncol, 28, pp.509~518 (2010)
6. Mauri D, "Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer : meta-analysis", J Natl Cancer Inst, 98, pp.1285~1291 (2006)
7. Becker T, "Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer", J Am Geriatr Soc, 60, pp.1761~1767 (2012)
8. Hadji P, "Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis", Crit Rev Oncol Hematol, 69, pp.73~82 (2009)
9. Lee SJ, "Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer", Calcif Tissue Int, 97, pp.551~559 (2015)
10. Kyvernitakis I, "Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer", J Cancer Res Clin Oncol, 140, pp.1671~1680 (2014)
11. Coleman RE, "Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study", Lancet Oncol, 8, pp.119~127 (2007)
12. Goss PE, "Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17", J Natl Cancer Inst, 97, pp.1262~1271 (2005)
13. Cuzick J, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 10-year analysis of the ATAC trial", Lancet Oncol, 11, pp.1135~1141 (2010)
14. Rabaglio M, "Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial", Ann Oncol, 20, pp.1489~1498 (2009)
15. Forbes JF, "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 100-month analysis of the ATAC trial", Lancet Oncol, 9, pp.45~53 (2008)
16. Amir E, "Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients : a systematic review and meta-analysis", J Natl Cancer Inst, 103, pp.1299~1309 (2011)
17. Taxel P, "Cancer treatment-induced bone loss in women with breast cancer and men with prostate cancer", J Endocr Soc, 2, pp.574~588 (2018)
18. Melton LJ 3rd, "Fracture risk in women with breast cancer : a population-based study", J Bone Miner Res, 27, pp.1196~1205 (2012)
19. Shamseer L, "Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P)2015 : elaboration and explanation", BMJ, 354, pp.i4086~ (2016)
20. Fraenkel M, "Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD : a retrospective analysis", NPJ Breast Cancer, 1, pp.15010~ (2015)
21. Hsieh E, "Vertebral fractures among breast cancer survivors in China : a cross-sectional study of prevalence and health services gaps", BMC Cancer, 18, pp.104~ (2018)
22. Kanis JA, "A high incidence of vertebral fracture in women with breast cancer", Br J Cancer, 79, pp.1179~1181 (1999)
23. Tsai CH, "Fracture in asian women with breast cancer occurs at younger age", PLoS One, 8, pp.e75109~ (2013)
24. Lo JC, "Bone and the perimenopause", Obstet Gynecol Clin North Am, 38, pp.503~517 (2011)
25. de Cremoux P, "Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women : pharmacological and clinical aspects", Bull Cancer, 91, pp.917~927 (2004)
26. Hofbauer LC, "From bone to breast and back-the bone cytokine RANKL and breast cancer", Breast Cancer Res, 13, pp.107~ (2011)
27. Kalder M, "Breast cancer and osteoporosis-management of cancer treatment-induced bone loss in postmenopausal women with breast cancer", Breast Care(Basel), 9, pp.312~317 (2014)
28. Sheean P, "Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors : a case-control study", J Cancer Surviv, 10, pp.21~30 (2016)
29. Boman A, "Receptor activator of nuclear factor kappa-B ligand(RANKL)but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis", Clin Rheumatol, 36, pp.1005~1012 (2017)
30. 이지연, "Stimulation of osteoclast migration and bone resorption by C–C chemokine ligands 19 and 21", Experimental and Molecular Medicine, 49, pp.1~13 (2017), 생화학분자생물학회
31. Fata JE, "The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development", Cell, 103, pp.41~50 (2000)
32. Tremollieres FA, "Osteoporosis management in patients with breast cancer : EMAS position statement", Maturitas, 95, pp.65~71 (2017)
33. Manolagas SC, "From estrogen-centric to aging and oxidative stress : a revised perspective of the pathogenesis of osteoporosis", Endocr Rev, 31, pp.266~300 (2010)
34. Maeda SS, "An overview on the treatment of postmenopausal osteoporosis", Arq Bras Endocrinol Metabol, 58, pp.162~171 (2014)
35. Yue W, "Effects of estrogen on breast cancer development : Role of estrogen receptor independent mechanisms", Int J Cancer, 127, pp.1748~1757 (2010)
36. Li-Han Hsu, "Estrogen, Estrogen Receptor and Lung Cancer", International Journal of Molecular Sciences, 18(8), pp.1713~ (2017), MDPI AG[DOI]
37. Nishimukai A, "Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases", Breast Cancer, 24, pp.245~253 (2017)
38. Banfi G, "Oxidative stress, free radicals and bone remodeling", Clin Chem Lab Med, 46, pp.1550~1555 (2008)
39. Domazetovic V, "Oxidative stress in bone remodeling : role of antioxidants", Clin Cases Miner Bone Metab, 14, pp.209~216 (2017)
40. Wauquier F, "Oxidative stress in bone remodelling and disease", Trends Mol Med, 15, pp.468~477 (2009)
41. Baek KH, "Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures", Calcif Tissue Int, 87, pp.226~235 (2010)
42. Fontani F, "Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL", OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1, Calcif Tissue Int, pp.2015, 96[DOI]
43. Ueno T, "N-acetyl cysteine protects osteoblastic function from oxidative stress", J Biomed Mater Res A, 99, pp.523~531 (2011)
44. Hecht F, "The role of oxidative stress on breast cancer development and therapy", Tumour Biol, 37, pp.4281~4291 (2016)
45. Yu T, "Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance", Chin J Cancer Res, 29, pp.237~252 (2017)
46. Chen Y, "Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b", Oncogene, 36, pp.4692~4705 (2017)
47. Bussard KM, "Tumor-associated stromal cells as key contributors to the tumor microenvironment", Breast Cancer Res, 18, pp.84~ (2016)
48. Ettinger B, "Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures", J Clin Endocrinol Metab, 83, pp.2239~2243 (1998)
49. Buzdar AU, "An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane", Cancer, 95, pp.2006~2016 (2002)
50. Pfeilschifter J, "Role of cytokines in postmenopausal bone loss", Curr Osteoporos Rep, 1, pp.53~58 (2003)
51. Shimodaira K, "Osteoblast cells(MG-63 and HOS)have aromatase and 5 alpha-reductase activities", Biochem Mol Biol Int, 39, pp.109~116 (1996)
52. Miki Y, "Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells : a possible androgenic bone protective effects induced by exemestane", Bone, 40, pp.876~887 (2007)

관련 논문AI추천